Sino Biopharmaceutical Ltd

HK

SINOB

Health Care

7.2 ₽

Current price

Sell
7.2 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    429 / 1328

  • Position in country

    921 / 1846

  • Return on Assets, %

    7.1

    -2.7

  • Net income margin, %

    17.5

    2.8

  • EBITDA margin, %

    28.7

    10.8

  • Debt to Equity, %

    41.2

    19.2

  • Intangible assets and goodwill, %

    4.5

    3.6

  • Revenue CAGR 3Y, %

    3.4

    8.5

  • Revenue Y, % chg

    -14

    0.5

  • P/E

    22.7

    22.7

  • P/BV

    1.5

    1.5

  • P/S

    1.8

    2.3

  • EV/S

    2.1

    2.4

  • EV/EBITDA

    7.6

    7.4

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    -92.4

    51.3

  • Forward P/E

    15.7

    15.6

  • Dividend Yield, %

    2.8

    1.7

  • Forward Dividend Yield, %

    0.1

    0.2

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    73.6

    30.3

  • Dividend Ex Date

    2023-10-04

Get an analytical review of this company

Competitors

Ranks

  • United Laboratories International Holdings Ltd

    00%

  • Grand Pharmaceutical Group Ltd

    00%

  • SSY Group Ltd

    00%

  • China Resources Pharmaceutical Group Ltd

    00%

  • China Traditional Chinese Medicine Holdings Co Ltd

    00%

  • China Medical System Holdings Ltd

    00%

  • Beijing Tong Ren Tang Chinese Medicine Co Ltd

    00%

  • Sino Biopharmaceutical Ltd

    00%

  • Eli Lilly and Co

    00%

  • HUTCHMED (China) Ltd

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Hong Kong

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    6548.6

  • Ticker

    SBHMY.PK

  • ISIN

    US82937X1037

  • IPO date

    2003-12-08

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-03-28

  • Date fact. publication of reports

    2023-12-31

Company Description

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: